ExCellThera Secures German NUB Status 1 Listing for Zemcelpro

Why It Matters

The NUB listing paves the way for early reimbursement and clinical uptake in Germany, the EU’s largest stem‑cell transplant market, accelerating access to a novel donor‑independent therapy. This could reshape treatment pathways for high‑risk blood‑cancer patients and boost ExCellThera’s commercial trajectory.

Key Takeaways

• Received German NUB Status 1 listing for Zemcelpro.
• Interest from 220 German hospitals for 2026 use.
• EC granted conditional marketing authorisation for blood cancers.
• Therapy uses UM171‑expanded CD34+ cells from cord blood.
• Regulatory submissions planned for US, Canada, Switzerland, UK.

Pulse Analysis

The emergence of UM171‑expanded cord‑blood cell products marks a turning point in hematopoietic stem‑cell transplantation. Zemcelpro combines expanded CD34+ progenitors with unexpanded CD34‑ cells, delivering a donor‑independent graft that can bridge the shortage of matched donors. Clinical data from more than 120 patients across Canada, Europe and the United States demonstrate comparable engraftment kinetics and safety profiles to traditional bone‑marrow transplants, positioning the therapy as a viable option for high‑risk hematologic malignancies.

Germany’s Neue Untersuchungs‑ und Behandlungsmethoden (NUB) programme offers a fast‑track pathway for innovative therapies, and a Status 1 listing signals both clinical relevance and potential reimbursement. With 220 hospitals indicating intent to use Zemcelpro by 2026, the listing could unlock a sizable market segment, given that Germany accounts for roughly 30% of Europe’s allogeneic transplant volume. Early adoption through individual NUB applications will also generate real‑world evidence, feeding into post‑market registries that support long‑term pricing and guideline inclusion.

Looking ahead, ExCellThera’s strategy extends beyond Europe. Parallel submissions to health authorities in the United States, Canada, Switzerland and the United Kingdom aim to replicate the German momentum on a global scale. Strategic partnerships are being explored to accelerate commercial rollout, while ongoing data collection will address payer concerns around cost‑effectiveness. If successful, Zemcelpro could set a new standard for off‑the‑shelf stem‑cell therapies, influencing both clinical practice and the broader biotech investment landscape.